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aimed to assess the long-term clinical and angiographic impact of SF
on Xience everolimus-eluting stent (EES) and Nobori biolimus-eluting
stent (BES) implantation.
METHODS From 2010 to 2013, 3246 lesions (1783 patients) were
treated with EES and 1618 lesions (986 patients) with BES, in which
follow-up angiography was performed within one year after index
procedure. SF was deﬁned as the separation of stent segments or stent
struts at follow-up angiography. The mid-term angiography was per-
formed at 8 months and the late-term at 20 months. ISR was deﬁned
as more than 50% restenosis. Late catch-up phenomenon was deﬁned
as ISR, excluding that within one year after index procedure.
RESULTS SF was observed in 1.7% (56/3246) of the lesions treated
with EES and 4.4% (72/1618) with BES. The median follow-up duration
of the study population was 1028 days (the ﬁrst and third quarters,
838 and 1275 days). The mid-term restenosis rate showed no signiﬁ-
cant difference between the EES and BES groups (40.7% versus 30.6%,
p¼0.26). The late catch-up phenomenon rate was signiﬁcantly lower
in the BES group (18.2% versus 2.4%, p¼0.04). Very late stent
thrombosis was none in the EES group, on the other hand, occurred in
one patient in the BES group. The three-year cumulative rates of any
TLR did not signiﬁcantly differ between the 2 groups (44.8% versus
29.7%, p¼0.07). A landmark analysis of the cumulative rates of any
TLR within and beyond one year is shown in the ﬁgure.
CONCLUSIONS The long-term clinical impact of SF could be different
between EES and BES implantation.
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BACKGROUND In second generation DES era, in-stent restenosis (ISR)
is not commonly seen but is still encountered occasionally. The
pathophysiology and mechanism of ISR after second generation DES
implantation have not been fully clariﬁed.
METHODS Patients who underwent follow-up coronary angio-
graphy (CAG) after ﬁrst (Cypher and Taxus) and second generationDES (Nobori, Promus Element, Resolute Integrity, and Xience) im-
plantation were examined. The ﬁrst scheduled CAG was performed at
six to nine months after percutaneous coronary intervention (PCI) and
the second at 18 to 24 months after PCI. ISR was deﬁned as lesions
more than 75% diameter stenosis at follow-up CAG. Optical coherence
tomography (OCT) was performed at the time of revascularization to
ISR. Then OCT imaging of second generation DES ISR of early (<1 year)
and late ( 1 year) phase were compared with ﬁrst generation DES ISR,
retrospectively.
RESULTS From April 2008 to January 2010, ﬁrst generation DES were
implanted in 805 lesions. From January 2011 to December 2014, sec-
ond generation DES were implanted in 1269 lesions in our hospital.
ISR rate were signiﬁcantly lower in second generation DES ISR (9.6%
(N¼77) vs 4.0% (N¼51), p<0.05). In qualitative OCT assessment of
second generation DES ISR in total, each ratio of homogeneous,
layered, heterogeneous, lipid rich attenuation, calciﬁed nodule tissue
morphologies were 54.0% and 16.2%, 18.9%, 5.4%, and 5.4% respec-
tively. Compared with ﬁrst generation DES ISR, both in early and late
ISR cases, homogeneous morphology was signiﬁcantly higher in sec-
ond generation DES ISR (61.1% vs 36.0%, and 47.3% vs 8.0%,
respectively, p<0.05).
CONCLUSIONS Homogeneous tissue morphology assessed by OCT
was more frequently found in second generation DES ISR than ﬁrst
generation DES ISR, especially in early phase (<1 year). This ﬁnding
suggests that neointimal hyperplasia is main mechanism in second
generation DES early ISR and arterial healing process is smooth like
bare metal stents implantation.
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BACKGROUND The thin-strut, everolimus-eluting, platinum chro-
mium PROMUS Element stent (Boston Scientiﬁc, Marlborough MA)
has shown favorable early outcomes up to 4 years post-implantation
for the treatment of de novo long lesions or lesions in small-caliber
vessels, but long-term follow-up has not been previously reported.
METHODS PLATINUM SV and LL are prospective, single-arm, multi-
national studies that enrolled patients with angina pectoris or docu-
mented silent ischemia and a single de novo native coronary artery
target lesion. PLATINUM SV enrolled 94 subjects with baseline vessel
diameter 2.25 mm to <2.50 mm and lesion length 28 mm, and
PLATINUM LL enrolled 102 patients with a target lesion >24
to 34 mm long with vessel diameter 2.50 to 4.25 mm. Follow-up
was performed for 5 years.
RESULTS Patients were predominantly male (SV: 72.3%, LL: 62.7%)
and approximately one third had diabetes (SV: 42.6%, LL: 30.0%). The
mean baseline reference vessel diameter (RVD) in SV was 2.0  0.3 mm
and lesion length was 14.2  7.0 mm. For the LL study, RVD was 2.6 
0.4 and mean lesion length was 24.4  8.2 mm. The primary endpoint,
1-year target lesion failure (TLF,; cardiac death, myocardial infarction
(MI) related to the target vessel, ischemia-driven target lesion revas-
cularization [TLR]), was 2.4% for SV and 3.2% for LL, both signiﬁcantly
less than prespeciﬁed performance goals (P<0.001 for each). At 5 years,
TLF, TLR, cardiac death, MI and ARC stent thrombosis (ST) had
occurred in 6 (7.0%), 3 (3.6%), 5 (5.9%), 2 (2.4%), and 0 (0%) patients
respectively in the SV trial and TLF, TLR, cardiac death, MI and ARC
stent thrombosis (ST) had occurred in 13 (13.6%), 7 (7.5%), 5 (5.9%), 1
(1.3%), and 0 (0%) patients respectively in the LL trial.
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TLF and revascularization rates with favorable safety outcomes for
the treatment of small vessels and long lesions through 5 years.
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BACKGROUND Recent study reported that arterial healing of drug
eluting stents was impaired with greater delay at the ﬂow divider
(high shear stress region) as compared with the opposite side of side
branch (SB) (low shear stress region). This study investigated the
differences in neointimal growth on stent struts between thin- and
thick-strut drug eluting stents (DES) implanted in coronary bifurca-
tion lesions by using optical coherence tomography (OCT).
METHODS Sixty-two bifurcation lesions treated with second genera-
tion DES were evaluated with OCT in 51 patients (66.1 y.o) at 6 to 12
months follow-up angiography. The stent strut was deﬁned as thin
when less than 100mm and thick when more than 100mm. Each lesions
were divided into thick-DES (n¼20; Nobori biolimus-eluting stents) or
thin-DES (n¼42; Xience everolimus-eluting stents and Resolute
Integrity zotarolimus-eluting stents). Neointimal coverage was
assessed based on cross-sectional OCT images containing SB at 400mm
interval, and separately evaluated according to three independent
regions: SB ostium (SO), the 1/2 circumference of the vessel wall
opposite to SB (LS; low share stress region), and the vessel wall
adjacent to SB (HS; high shear stress region). Incidence of uncovered
struts and neointimal thickness were measured on the cross sectional
OCT images.
RESULTS Total of 2437 struts were analyzed in this study (thick-DES:
911 vs. thin-DES: 1526). The incidence of uncovered struts was
signiﬁcantly higher at HS region compared with LS regions in thick-
DES (16.8% vs. 7.9%, p<0.01), while there was no signiﬁcant differ-
ence in thin-DES at both HS and LS region (7.3% vs. 5.4%, p¼0.1643).
The incidence of uncovered struts was signiﬁcantly higher in thick-
DES compared with thin-DES at HS region (16.8% vs 7.3%, p<0.01),
while there was no signiﬁcant difference at both LS and SO region
(7.9% vs. 5.4%, p¼0.0846; 34.7% vs. 36.4%, p¼0.7606, respectively).
Neointimal thickness was signiﬁcantly smaller in thick-DES compared
with thin-DES at both HS and LS region (69.446.6mm vs.
99.970.8mm, p<0.01; 72.247.6mm vs. 98.569.5mm, p<0.01,
respectively), while there was no signiﬁcant difference at SO region
(48.731.8mm vs. 48.736.1mm, p¼0.8386).
CONCLUSIONS Thin strut DES was homogeneously endothelialized in
bifurcation lesions and may have more favorable arterial healing
response for bifurcation lesions compared with thick strut DES.
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BACKGROUND Chronic total occlusions (CTO), deﬁned by TIMI 0 ﬂow
and duration of occlusion of more than 3 month, are associated with a
higher risk of restenosis compared to other lesion types. We evaluated
clinical and angiographic results after recanalization of CTOs with the
Sirolimus eluting Orsiro hybrid stent with bioresorbable polymer
coating. Orsiro is a cobalt chromium stent with an absorbable polymer
and thin struts of 60 mm. We compared two consecutive patient series
undergoing recanalization for CTO with either the Orsiro Sirolimus-
eluting stent (O-SES) or a Zotarolimus- eluting stent (ZES)
METHODS 74 patients after successful recanalization of a true CTO in
a native coronary artery where enrolled in our prospective registry
(clinical trials.gov NCT02162082) and compared with 57 patients
treated with a Zotarolimus-eluting stent. In 68 % vs 50% CTO recan-
alization was performed by antegrade and in 32%vs 5% by retrograde
approach. After pre-dilatation a mean of 2.71.3 (range 1-6) Orsiro
stents and 2.71.2 (1-7) ZES were implanted with a mean length of
81.930.6mm. 32.4% (N¼ 24/74) of patients in the Orsiro group suf-
fered from diabetes mellitus and 28.1%(N¼16/57)in the Zotarolimus
group. In 66.2% vs 61.4% CTO was located in RCA, 18.9%vs15.8% in
LCX and in 14.9%vs 22.8% in LAD. Reference diameter post PCI was
3.040.49mm (3.190.56mm), MLD 2.820.51mm (3.060.48mm)
and percent diameter stenosis 7.610.0 (3.78.3). Dual antiplatelet
therapy (DAPT) was recommended for 12 months with aspirin and
clopidogrel. Control angiography was scheduled after 9 and clinical
follow-up after 12 month. The primary angiographic outcome was in-
stent late lumen loss. Secondary angiographic endpoints include
minimal luminal diameter, percentage of diameter stenosis, binary
restenosis. Primary clinical outcome measures were target lesion
revascularization rate (TLR) and major adverse cardiac events (MACE)
deﬁned as composite of cardiac death, myocardial infarction related
to the target vessel and target vessel revascularization.
RESULTS The primary endpoint in-stent late lumen loss was
0.240.53mm for the Orsiro stent compared with 0.590.72mm for
the Zotarolimus stent (p¼0.01), MLD was 1.990.63mm versus
1.870.80mm (p¼0.86), percent diameter stenosis 24.719.2% vs.
27.728.7% (p¼0.58), respectively. TLR was 9.7% for O-SES and 10.5 %
for ZES, resulting in a total MACE rate of 10.8% vs 12.3% (p¼0.79). Of
note, there was no deﬁnite or probable stent thrombosis according to
ARC criteria in both groups within 12 months DAPT treatment.
CONCLUSIONS Treatment of true CTO lesions with the Sirolimus
eluting abluminal coated Orsiro stent resulted in a signiﬁcantly lower
in-stent late lumen loss compared with Zotarolimus eluting stents and
no occurrence of deﬁnite or probable stent thrombosis with a 12
months dual antiplatelet therapy. Clinical results were similar to
Zotarolimus eluting stents.
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BACKGROUND Several studies have performed the comparison of
outcomes between 1st generation drug eluting stent Sirolimus-Eluting
Stent (SES) and 2nd generation drug eluting stent Everolimus-Eluting
